Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases. Endeavor’s lead investigational candidate, taladegib (ENV-101), is an inhibitor of the Hedgehog (Hh) signaling pathway in clinical development for the treatment of fibrotic lung disease, including idiopathic pulmonary fibrosis (IPF).
OUR SCIENCE
Our approach is focused on developing therapies that precisely target the root cause of disease to deliver transformational clinical benefits and the potential to change treatment expectations.
Our leadership team has deep experience developing drug candidates into leading medicines that make a meaningful difference in patients’ lives.
OUR LEADERSHIP
OUR CULTURE
We have a vibrant and passionate culture that reflects our shared mission to deliver new therapeutic options for patients with life-threatening diseases.
LATEST NEWS
Endeavor BioMedicines to Present Results from Phase 2a Trial of Taladegib (ENV-101) in an ALERT Session at European Respiratory Society (ERS) Congress 2025
SAN DIEGO – September 10, 2025 – Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced that data from a Phase 2a trial evaluating the safety and efficacy of taladegib (ENV-101) in patients with idiopathic pulmonary fibrosis...
Endeavor BioMedicines Receives Orphan Drug Designation from the U.S. Food and Drug Administration and European Commission for Taladegib (ENV-101) for the Treatment of Idiopathic Pulmonary Fibrosis
SAN DIEGO – July 16, 2025 – Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today announced that both the European Commission (EC) and the U.S. Food and Drug Administration (FDA) have granted Orphan Drug...
Endeavor BioMedicines Presents New Clinical Findings From Post Hoc Analysis of Phase 2a Clinical Trial Evaluating ENV-101 in Patients with Idiopathic Pulmonary Fibrosis
Findings presented at the American Thoracic Society 2025 International Conference corroborate previous findings and provide important new clinical evidence supporting ENV-101 SAN DIEGO – May 20, 2025 – Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases,...
Fibrotic Lung Disease
Data from a Phase 2a, randomized, double-blind, placebo-controlled 12-week clinical trial suggest Endeavor’s investigational candidate taladegib is the first to show improvement from baseline in lung function combined with evidence it may reverse the course of disease in IPF patients.